Recent pharmaceutical interventions, specifically glucagon-like peptide-1 receptor agonist drugs (GLP-1RA), have advanced medical treatment for obesity and glycemic control (3). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.